The absence of TET activity diminished the expression of TH1-type chemokines and tumor-infiltrating lymphocytes, thereby allowing an evasion of antitumor immunity and resistance to anti-PD-L1 therapy [25]. This evidence concerns the gene CD274 and neoplasm.